Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AYLA

Ayala Pharmaceuticals (AYLA) Stock Price, News & Analysis

Ayala Pharmaceuticals logo

About Ayala Pharmaceuticals Stock (NASDAQ:AYLA)

Advanced Chart

Key Stats

Today's Range
$0.50
$0.50
50-Day Range
$0.38
$0.58
52-Week Range
$0.36
$7.31
Volume
N/A
Average Volume
76,300 shs
Market Capitalization
$7.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive AYLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AYLA Stock News Headlines

OS Therapies to acquire listeria programs from Ayala Pharmaceuticals
OS Therapies Expands Pipeline With Ayala Asset Acquisition, Stock Up
Genesis 14:13-17 [HIDDEN MEANING?]
A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthright” — a $150 trillion wealth vault that’s remained untouched for over a century. Jim Rickards believes President Trump is about to unleash it — and investors who move first could come out on top. The full story is now available.
ADXS Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals (ADXS) Earnings Dates & Reports
Advaxis, Inc.: Advaxis and Ayala Pharmaceuticals Complete Merger
See More Headlines

AYLA Stock Analysis - Frequently Asked Questions

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) released its quarterly earnings results on Monday, November, 15th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.12. The firm had revenue of $0.63 million for the quarter, compared to the consensus estimate of $0.82 million. Ayala Pharmaceuticals had a negative trailing twelve-month return on equity of 182.13% and a negative net margin of 2,341.69%.

Ayala Pharmaceuticals (AYLA) raised $50 million in an initial public offering (IPO) on Friday, May 8th 2020. The company issued 3,300,000 shares at a price of $14.00-$16.50 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Oppenheimer and Raymond James were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ayala Pharmaceuticals investors own include HubSpot (HUBS), Netflix (NFLX), ForgeRock (FORG), Bank of America (BAC), ConocoPhillips (COP) and Diamondback Energy (FANG).

Company Calendar

Last Earnings
11/15/2021
Today
7/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AYLA
CIK
1797336
Fax
N/A
Employees
35
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.52)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$40.25 million
Net Margins
-2,341.69%
Pretax Margin
-2,298.60%
Return on Equity
-182.13%
Return on Assets
-139.83%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.28
Quick Ratio
2.28

Sales & Book Value

Annual Sales
$3.51 million
Price / Sales
2.13
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.45 per share
Price / Book
0.21

Miscellaneous

Outstanding Shares
14,821,000
Free Float
14,287,000
Market Cap
$7.46 million
Optionable
Not Optionable
Beta
1.98
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:AYLA) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners